ABBV vs NVS
AbbVie and Novartis AG, both Healthcare
AbbVie is the larger company at $382B against $281B. On trailing earnings NVS is the cheaper of the two at a P/E of 23.3 against 74.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year NVS returned +40% against +37% for ABBV. Ryufin's sector-relative Smart Score puts NVS ahead, 8/10 against 6/10.
| Figure | ABBV | NVS |
|---|---|---|
| Last close | $263 | $158 |
| Market cap | $382B | $281B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 74.3 | 23.3 |
| Dividend yield | 2.5% | n/a |
| 1-year return | +37% | +40% |
| 5-year return | +170% | +106% |
| Ryufin Smart Scoresector-relative, 1–10 | 6/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AbbVie
Revenue of $17B in Q2 2026, net income $3.6B. Its largest reported line is SKYRIZI, 36% of the disclosed total.
Novartis AG
Revenue of $27B in H2 2025, net income $6.3B.
Open these two in the interactive comparison to add more names, change the period or read the correlation.